Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines

详细信息    查看全文

• 作者：Cuiqing Ma^a ; ^f ; ¹ ; Ye Li^a ; ¹ ; Lili Wang^a ; Guangyu Zhao^b ; Xinrong Tao^c ; Chien-Te K. Tseng^c ; ^d ; Yusen Zhou^b ; Lanying Du^a ; ^{ldu@nybloodcenter.org" class="auth_mail} ; Shibo Jiang^a ; ^e ; ^{sjiang@nybloodcenter.org" class="auth_mail}
• 关键词：MERS-CoV ; Spike protein ; Receptor-binding domain ; Mucosal immune response ; Systemic immune response ; Neutralizing antibody
• 刊名：Vaccine
• 出版年：11 April, 2014
• 年：2014
• 卷：32
• 期：18
• 页码：2100-2108
• 全文大小：2232 K

文摘

Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) was originally identified in Saudi Arabia in 2012. It has caused MERS outbreaks with high mortality in the Middle East and Europe, raising a serious concern about its pandemic potential. Therefore, development of effective vaccines is crucial for preventing its further spread and future pandemic. Our previous study has shown that subcutaneous (s.c.) vaccination of a recombinant protein containing receptor-binding domain (RBD) of MERS-CoV S fused with Fc of human IgG (RBD-Fc) induced strong systemic neutralizing antibody responses in vaccinated mice. Here, we compared local and systemic immune responses induced by RBD-Fc via intranasal (i.n.) and s.c. immunization pathways. We found that i.n. vaccination of MERS-CoV RBD-Fc induced systemic humoral immune responses comparable to those induced by s.c. vaccination, including neutralizing antibodies, but more robust systemic cellular immune responses and significantly higher local mucosal immune responses in mouse lungs. This study suggests the potential of developing MERS-CoV RBD protein into an effective and safe mucosal candidate vaccine for prevention of respiratory tract infections caused by MERS-CoV.